ORIGINAL ARTICLE

Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?

S Leibl and F Moinfar

Department of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria

Correspondence to:
Correspondence to:
Dr S Leibl
Department of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria; sebastian.leibl{at}klinikum-graz.at

Background: Metaplastic carcinomas (MCs) of the breast rarely express steroid receptors and Her-2, which minimises the options for adjuvant treatment in patients with advanced disease.

Aims: To investigate the possible eligibility of patients with MCs for epidermal growth factor receptor (EGFR) targeted treatment.

Methods: Immunohistochemical assessment of the expression of steroid receptors and four members of the EGFR/Her family (EGFR/Her-1–4) in 20 MCs (eight with heterologous elements, seven spindle cell MCs, four carcinosarcomas, and one matrix producing carcinoma). Fourteen of the 20 MCs were positive for EGFR (Her-1). Among these cases, 1+, 2+, and 3+ reactivity were seen in two, four, and eight cases, respectively. Her-2 was only present in one MC with 1+ reactivity. Her-3 (1+ reactivity), Her-4 (2+ reactivity), and the androgen receptor (2+ reactivity) were also expressed by one tumour. Oestrogen and progesterone receptors (3+ reactivity each) were detected in the epithelial component only of two carcinosarcoma-type MCs.

Conclusions: MCs express EGFR considerably more frequently than the types of breast carcinomas that have been investigated previously. Although molecular analyses for possible genetic alterations in the EGFR might be required, these results suggest that women suffering from this aggressive form of breast carcinoma might benefit from treatment with protein kinase inhibitors, such as gefitinib.

Abbreviations: EGFR, epidermal growth factor receptor; MC, metaplastic breast carcinoma; NSCLC, non-small cell lung cancer

Keywords: metaplastic carcinoma; breast; epidermal growth factor receptor; tyrosine kinase inhibitor; gefitinib

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Korsching, E, Jeffrey, S S, Meinerz, W, Decker, T, Boecker, W, Buerger, H (2008). Basal carcinoma of the breast revisited: an old entity with new interpretations. J. Clin. Pathol. 61: 553-560 [Abstract] [Full Text]  
• Gilbert, J. A., Goetz, M. P., Reynolds, C. A., Ingle, J. N., Giordano, K. F., Suman, V. J., Blair, H. E., Jenkins, R. B., Lingle, W. L., Reinholz, M. M., Adjei, A. A., Ames, M. M. (2008). Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Molecular Cancer Therapeutics 7: 944-951 [Abstract] [Full Text]